Mithra Pharmaceuticals SA

LSE:0R91 Stock Report

Market Cap: €12.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Mithra Pharmaceuticals has a total shareholder equity of €-103.3M and total debt of €267.4M, which brings its debt-to-equity ratio to -258.9%. Its total assets and total liabilities are €286.5M and €389.8M respectively.

Key information

-258.9%

Debt to equity ratio

€267.37m

Debt

Interest coverage ration/a
Cash€8.98m
Equity-€103.25m
Total liabilities€389.80m
Total assets€286.55m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 0R91 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0R91 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0R91 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 0R91's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0R91 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 0R91 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.9% each year


Discover healthy companies